Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 24 , ISSUE 10 ( October, 2020 ) > List of Articles

Original Article

A Multicenter Questionnaire-Based Study to Know the Awareness and Medical Treatment Plan of Physicians Involved in the Management of COVID-19 Patients

Hunasaghatta Chandrappa Deepa

Keywords : Coronavirus disease 2019, Cytokine storm, Hydroxychloroquine, Medical management, Remdesivir

Citation Information : Deepa HC. A Multicenter Questionnaire-Based Study to Know the Awareness and Medical Treatment Plan of Physicians Involved in the Management of COVID-19 Patients. Indian J Crit Care Med 2020; 24 (10):919-925.

DOI: 10.5005/jp-journals-10071-23567

License: CC BY-NC 4.0

Published Online: 25-01-2021

Copyright Statement:  Copyright © 2020; The Author(s).


Introduction: The pandemic coronavirus disease 2019 (COVID-19) is on the raise in our country and there is there is no specific treatment modality available presently. The treatment of the disease largely remains symptomatic but repurposed drugs used to treat other disease conditions are being used to treat moderate to severe form of the disease. As the clinical trials for these drugs are ongoing, we conducted this survey to know the physicians’ medical treatment plan for COVID-19 patients. Materials and methods: It was a Web-based questionnaire study. Institutional ethical committee clearance was taken before the commencement of the study. There were a total of 17 questions, the first 6 being about the demographics, place of work, and whether the clinician was involved in the care of COVID-19 patients. Subsequent 11 questions were to assess physician's awareness and plan of the medical management of the COVID-19 patients. Results: The majority of the clinicians were aware of the various treatment modalities available for the treatment of COVID-19. Regarding the plan for use of hydroxychloroquine (HCQ), 55% of the total respondents intended to use the drug in combination with azithromycin, even as 62% agreed that there was no clear evidence yet. About 90% of all clinicians, from junior residents to consultants, were monitoring electrocardiogram (ECG) during HCQ therapy; however, there were 10% of physicians who were not practising ECG monitoring. About 68% of clinicians were aware of the various therapeutic options being tested, like convalescent plasma, lopinavir–ritonavir, and 64% knew about remdesivir. There was divergence regarding the use of steroids in a cytokine storm among the physicians, with only 39% of consultants planning to use steroids whereas about 50% of junior residents and 79% of junior consultants were planning to use the drug. Conclusion: The majority of the clinicians involved in the management of COVID-19 were aware of the various drug modalities available for treatment. However, more emphasis on the adverse effects and possible drug interactions is required. There is disaccord regarding the use of steroids in cytokine storm in COVID-19 and further guidelines and educational programs should address these issues. Clinical significance: Clinicians have to be made more aware of the possible adverse effects and drug interactions of the medications used for the treatment of COVID-19. The treatment of the serious, cytokine storm syndrome and the role of steroids must be elucidated as soon as it is feasible.

PDF Share
  1. Million M, Lagier JC, Gautret P, Colson P, Fournier PE, Amrane S, et al. Full-length title: early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis 2020:101738. DOI: 10.1016/j.tmaid.2020.101738.
  2. Kalil AC. Treating COVID-19—off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA 2020.
  3. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA 2020;323(18):1824–1836.
  4. Ornstein MH, Sperber K. The anti-inflammatory and antiviral effects of hydroxychloroquine in two patients with acquired immunodeficiency syndrome and active inflammatory arthritis. Arthritis Rheum 1996;39(1):157–161. DOI: 10.1002/art.1780390122.
  5. Wang LF, Lin YS, Huang NC, Yu CY, Tsai WL, Chen JJ, et al. Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery. J Interf Cytokine Res 2015;35(3):143–156. DOI: 10.1089/jir.2014.0038.
  6. Kumar A, Singh A, Shaikh A, Singh R. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: a systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr 2020;14(3):241–246. DOI: 10.1016/j.dsx.2020.03.011.
  7. National Task Force for COVID-19 in India. Recommendation for empiric use of hydroxychloroquine for prophylaxis of SARS-CoV-2 infection; 2020. Available from the website of Ministry of Health and Family Welfare, accessed on 1st June 2020.
  8. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19—Preliminary report. N Engl J Med 2020. Available from:
  9. Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 days in patients with severe COVID-19. N Engl J Med 2020. Available from:
  10. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med 2020;382(24):2327–2336. DOI: 10.1056/NEJMoa2007016.
  11. Bongiovanni M, Cicconi P, Landonio S, Meraviglia P, Testa L, Di Bagio A, et al. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals. Int J Antimicrob Agents 2005;26(1):88–91. DOI: 10.1016/j.ijantimicag.2005.03.003.
  12. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020;382(19):1787–1799. DOI: 10.1056/NEJMoa2001282.
  13. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229):1033–1034. DOI: 10.1016/S0140-6736(20)30628-0.
  14. Nile SH, Nile A, Qiu J, Li L, Jia X, Kai G. COVID-19: pathogenesis, cytokine storm, and therapeutic potential of interferons. Cytokine Growth Factor Rev 2020;53:66–70. DOI: 10.1016/j.cytogfr.2020.05.002Available from:
  15. Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the Rose study. Ann Rheum Dis 2012;71(2): 198–205. DOI: 10.1136/ard.2010.148700. Available from:
  16. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A 2020;117(20):10970–10975. DOI: 10.1073/pnas. 2005615117.
  17. World Health Organization. Clinical management of COVID-19. Interim guidance. 27 May 2020.
  18. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020;395(10223):473–475. DOI: 10.1016/S0140-6736(20) 30317-2.
  19. Rajendran K, Narayanasamy K, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: systematic review. J Med Virol 2020. DOI: 10.1002/jmv.25961.
  20. Casadevall A, Joyner MJ, Pirofski LA. A randomized trial of convalescent plasma for COVID-19-potentially hopeful signals. JAMA 2020. Available from:
  21. Modi PD, Nair G, Uppe A, Modi J, Tuppekar B, Gharpure AS, et al. COVID-19 awareness among healthcare students and professionals in Mumbai metropolitan region: a questionnaire-based survey. Cureus 2020;12(4):e7514.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.